Fig. 1From: 18F-FDG PET/CT response in a phase 1/2 trial of nab-paclitaxel plus gemcitabine for advanced pancreatic cancerWaterfall plot of best responses by 18F-FDG PET/CT. CMR, complete metabolic response; CT, computed tomography; nab-P, nab-paclitaxel; PET, positron emission tomography; PMR, partial metabolic response; SMD, stable metabolic disease. a The blue circle represents 0% best response from a single patient in the nab-P 100 mg/m2 cohortBack to article page